Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. - Gubin MM; Zhang X; Schuster H; Caron E; Ward JP; Noguchi T; Ivanova Y; Hundal J; Arthur CD; Krebber WJ; Mulder GE; Toebes M; et al. (Nature, 2014)